{"nctId":"NCT03519386","briefTitle":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","startDateStruct":{"date":"2018-07-26","type":"ACTUAL"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"count":590,"armGroups":[{"label":"Implant Group 1","type":"EXPERIMENTAL","interventionNames":["Combination Product: G2-TR intraocular implant containing travoprost"]},{"label":"Implant Group 2","type":"EXPERIMENTAL","interventionNames":["Combination Product: G2-TR intraocular implant containing travoprost"]},{"label":"Control Group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sham surgery + active-comparator eye drops"]}],"interventions":[{"name":"G2-TR intraocular implant containing travoprost","otherNames":["Implant Group"]},{"name":"Sham surgery + active-comparator eye drops","otherNames":["Control Group"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with open-angle glaucoma or ocular hypertension.\n* C/D ratio â‰¤ 0.8\n* Zero to three preoperative ocular hypotensive medications\n\nExclusion Criteria:\n\n* Active corneal inflammation or edema.\n* Retinal disorders not associated with glaucoma.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative","description":"Change from time-matched baseline in IOP at 8AM and 10AM at Day 10, Week 6 and Month 3.\n\nDay 10 8AM IOP minus Baseline 8AM IOP; Day 10 10AM IOP minus Baseline 10AM IOP; Week 6 8AM IOP minus Baseline 8AM IOP; Week 6 10AM IOP minus Baseline 10AM IOP; Month 3 8AM IOP minus Baseline 8AM IOP; Month 3 10AM IOP minus Baseline 10AM IOP.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.40","spread":"0.24"},{"groupId":"OG001","value":"-8.48","spread":"0.24"},{"groupId":"OG002","value":"-7.69","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.35","spread":"0.24"},{"groupId":"OG001","value":"-8.44","spread":"0.24"},{"groupId":"OG002","value":"-7.20","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.34","spread":"0.24"},{"groupId":"OG001","value":"-7.26","spread":"0.25"},{"groupId":"OG002","value":"-7.09","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.59","spread":"0.24"},{"groupId":"OG001","value":"-7.62","spread":"0.24"},{"groupId":"OG002","value":"-6.85","spread":"0.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.59","spread":"0.26"},{"groupId":"OG001","value":"-6.59","spread":"0.26"},{"groupId":"OG002","value":"-6.69","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.56","spread":"0.26"},{"groupId":"OG001","value":"-6.68","spread":"0.26"},{"groupId":"OG002","value":"-6.52","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Mean IOP (Control Group vs. Each Implant Group) Through 12 Months Postoperative","description":"Difference in mean IOP, between each test group and the control group, for IOP measurements through the Month 12 follow-up visit","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":200},"commonTop":["intraocular pressure increased","iritis"]}}}